Coronary Artery Disease
Conditions
Keywords
Coronary artery disease, Intermediate coronary lesion, Coronary physiology, vFFR
Brief summary
The FAST III is a randomized controlled, open-label, multicenter, international, non-inferiority, strategy trial. A total of 2228 participants will be randomized in a 1:1 fashion to either vFFR- or FFR guided revascularization. Patients will be consented prior to the procedure and then followed up to 12 (+1) months after randomization. The primary endpoint is analyzed at 12 months after randomization. Approximately 35 sites in 7 European countries (Netherlands, Ireland, United Kingdom, Germany, Italy, Spain, and France).
Detailed description
The FAST III is a randomized controlled, open-label, multicenter, international, non-inferiority, strategy trial of a vFFR guided strategy as compared to a FFR guided strategy to guide coronary revascularization in 2228 subjects with intermediate coronary artery lesions. Patients are screened for inclusion/exclusion criteria after the indication for coronary catheterization is established. After providing informed consent, patients are enrolled. Randomization is performed in the randomization module of the EDC system with an allocation ratio of 1:1 and stratification by center. The primary endpoint is a composite of all-cause death, any myocardial infarction, or any revascularization at 1 year post-randomization. All deaths and major cardiovascular events, including the individual components of primary and secondary endpoints are adjudicated by an independent Clinical Events Committee (CEC), using standardized definitions. An independent Data and Safety Monitoring Board (DSMB) will formally review the accumulating data to ensure there is no avoidable increased risk for harm to participants. The FAST III trial is performed in accordance with the Declaration of Helsinki, Good Clinical Practice (GCP), ISO 14155:2020, EC requirements and country specific regulations.
Interventions
DEVICEvFFR guided revascularization
3D-angio-based vessel FFR (CAAS, Pie Medical Imaging, Maastricht, The Netherlands) uses 3-Dimensional Quantitative Coronary Angiography (3D-QCA) for functional assessment of coronary stenosis. vFFR is calculated using two angiographic views with at least 30 degrees difference in rotation/angulation to generate the 3D reconstruction of the coronary artery.
DEVICEFFR guided revascularization
Fractional flow reserve (FFR) is a technique used in coronary catheterization to measure pressure differences across a coronary artery stenosis (narrowing, usually due to atherosclerosis) to determine the likelihood that the stenosis impedes oxygen delivery to the heart muscle (myocardial ischemia)
Sponsors
ECRI bv
Siemens Healthineers AG
Pie Medical Imaging
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The patient must be ≥18 years of age 2. Presenting with silent ischemia, stable angina, or non-ST-elevation acute coronary syndrome (NSTE-ACS) 3. Coronary artery disease with at least one native artery in which the stenosis severity is questionable (typically 30-80% stenosis) 4. FFR assessment and vFFR assessment feasible 5. The patient is willing and able to cooperate with study procedures and follow-up until study completion 6. Subject is able to confirm understanding of risks, benefits and treatment alternatives and he/she provides informed consent prior to any protocol-related procedure, as approved by the appropriate Ethics Committee
Exclusion criteria
1. ST-elevation myocardial infarction (STEMI) at presentation 2. Cardiogenic shock or severe hemodynamic instability at the time of intervention (heart rate\<50 beats per minute, systolic blood pressure \<90mmHg) or use of left ventricular assist device 3. Any target vessel with a distal Thrombolysis In Myocardial Infarction (TIMI) flow \<3. 4. Presence of thrombus in intermediate target lesion. 5. Known untreated severe valvular heart disease 6. Target lesion is located in or supplied by an arterial or venous bypass graft 7. History of cardiac allograft transplantation 8. Aorto-ostial lesions with an estimated diameter stenosis \>50% 9. Severe tortuosity precluding the acquisitions of 2 orthogonal projections of the target vessel with minimal overlap or foreshortening. 10. Absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or adenosine 11. Non-cardiac co-morbidities with a life expectancy less than 1 year 12. Currently participating in another trial that is not yet at its primary endpoint. The patient is not allowed to participate in another investigational device or drug study until the trial primary endpoint time point is achieved and may only be enrolled once in the study 13. Women of childbearing potential who do not have a negative pregnancy test within 24 hours before the procedure 14. Subject belongs to a vulnerable population (per Investigator's judgment) or subject unable to read or write
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of the composite of all-cause death, any myocardial infarction, or any revascularization | 1 year | Procedural myocardial infarction (MI) is adjudicated according to the ARC-2 consensus and spontaneous MI according to the 4th Universal definition of MI. |
Secondary
| Measure | Time frame |
|---|---|
| Rate of patient-oriented composite endpoint (POCE) defined as all-cause death, any stroke, any myocardial infarction, and any revascularization | 1 year |
| Rate of device-oriented composite endpoint (DOCE) defined as the composite of cardiovascular death, target-vessel MI, clinically indicated repeat revascularization of the target lesion | 1 year |
| Rate of study-oriented composite endpoint (SOCE) defined as the composite of cardiovascular death, study-vessel or target vessel MI, or study-vessel or target vessel revascularization | 1 year |
| Rate of target-vessel failure defined as a composite of cardiac death, target vessel myocardial infarction, or clinically indicated target-vessel revascularization | 1 year |
| Rate of target-lesion failure defined as a composite of cardiac death, target vessel myocardial infarction, or clinically indicated target-lesion revascularization | 1 year |
| Rate of study-vessel failure defined as a composite of cardiac death, study vessel myocardial infarction, or clinically indicated study-vessel revascularization | 1 year |
| Rate of definite and probable stent thrombosis | 1 year |
Countries
France, Germany, Ireland, Italy, Netherlands, Spain, United Kingdom
Contacts
PRINCIPAL_INVESTIGATORJoost Daemen, MD, PhD
Erasmus Medical Center
STUDY_DIRECTORErnest Spitzer, MD
European Cardiovascular Research Institute
Outcome results
None listed